0.05% atropine on control of myopia progression in Chinese school children: a randomized 3-year clinical trial
AIM: To evaluate the effect of 0.05% atropine on the control of myopia for 2y (phase I) and on spherical equivalent refraction (SER) progression for 1y (phase II) after its withdrawal in Chinese myopic children. METHODS: Totally 142 children with myopia were randomly assigned to the 0.05% atropine g...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2023-06-01
|
| Series: | International Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://ies.ijo.cn/en_publish/2023/6/20230617.pdf |
| _version_ | 1797816139181457408 |
|---|---|
| author | Qin Zhu Guang-Yong Tang Zhi-Juan Hua Li-Ping Xue Yuan Zhou Jie-Ying Zhang Ying-Ting Zhu Xiao-Fan Zhang |
| author_facet | Qin Zhu Guang-Yong Tang Zhi-Juan Hua Li-Ping Xue Yuan Zhou Jie-Ying Zhang Ying-Ting Zhu Xiao-Fan Zhang |
| author_sort | Qin Zhu |
| collection | DOAJ |
| description | AIM: To evaluate the effect of 0.05% atropine on the control of myopia for 2y (phase I) and on spherical equivalent refraction (SER) progression for 1y (phase II) after its withdrawal in Chinese myopic children. METHODS: Totally 142 children with myopia were randomly assigned to the 0.05% atropine group or to the placebo group. In phase I, children received 1 treatment for each eye daily. In phase II, the patients received no treatment. Axial length (AL), SER, intraocular pressure (IOP) and atropine-related side effects were assessed at 6 months' intervals. RESULTS: During phase I, the mean change of SER was -0.46±0.30 D in the atropine group, compared to -1.72±1.12 D in the placebo group (P<0.001). The mean change of AL in the atropine group (0.26±0.30 mm) was significantly shorter than that in the placebo group (0.76±0.62 mm, P=0.002). In addition, in phase II (12mo after the withdrawal of atropine), there was no significant difference in AL change from the atropine group, when compared with that from the placebo group (0.31±0.25 mm vs 0.28±0.26 mm, P>0.05). Furthermore, the change in SER from the atropine group was 0.50±0.41 D, which was significantly lower than 0.72±0.60 D from placebo group, (P<0.05). Finally, there were no statistically significant differences in IOP between the treatment and control groups at any stages (all P>0.05). CONCLUSION: The use of 0.05% atropine for two consecutive years may effectively control elongation of AL and thus progression of myopia, without significant SER progression 1y after atropine withdrawal. Therefore, treatment with 0.05% atropine daily for 2y is effective and safe. |
| first_indexed | 2024-03-13T08:33:17Z |
| format | Article |
| id | doaj.art-dba256bdcf214f5fbb323654f3a930ec |
| institution | Directory Open Access Journal |
| issn | 2222-3959 2227-4898 |
| language | English |
| last_indexed | 2024-03-13T08:33:17Z |
| publishDate | 2023-06-01 |
| publisher | Press of International Journal of Ophthalmology (IJO PRESS) |
| record_format | Article |
| series | International Journal of Ophthalmology |
| spelling | doaj.art-dba256bdcf214f5fbb323654f3a930ec2023-05-31T01:42:11ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982023-06-0116693994610.18240/ijo.2023.06.17202306170.05% atropine on control of myopia progression in Chinese school children: a randomized 3-year clinical trialQin Zhu0Guang-Yong Tang1Zhi-Juan Hua2Li-Ping Xue3Yuan Zhou4Jie-Ying Zhang5Ying-Ting Zhu6Xiao-Fan Zhang7Xiao-Fan Zhang. Department of Pediatric Ophthalmology, Affiliated Hospital of Yunnan University, Kunming 650021, Yunnan Province, China. 113140405@qq.com; Ying-Ting Zhu. Research and Development Department, BioTissue (TissueTech, Inc.), 7230 Corporate Center Drive, Suite B, Miami, FL 33126, USA. yzhu@BioTissue.comDepartment of Ophthalmology, People's Hospital of Xundian County, Kunming 655200, Yunnan Province, ChinaDepartment of Pediatric Ophthalmology, Affiliated Hospital of Yunnan University, Kunming 650021, Yunnan Province, ChinaDepartment of Pediatric Ophthalmology, Affiliated Hospital of Yunnan University, Kunming 650021, Yunnan Province, ChinaDepartment of Pediatric Ophthalmology, Affiliated Hospital of Yunnan University, Kunming 650021, Yunnan Province, ChinaDepartment of Pediatric Ophthalmology, Affiliated Hospital of Yunnan University, Kunming 650021, Yunnan Province, ChinaBioTissue (Tissue Tech, Inc.), Ocular Surface Center, and Ocular Surface Research & Education Foundation, Miami, FL 33126, USADepartment of Pediatric Ophthalmology, Affiliated Hospital of Yunnan University, Kunming 650021, Yunnan Province, ChinaAIM: To evaluate the effect of 0.05% atropine on the control of myopia for 2y (phase I) and on spherical equivalent refraction (SER) progression for 1y (phase II) after its withdrawal in Chinese myopic children. METHODS: Totally 142 children with myopia were randomly assigned to the 0.05% atropine group or to the placebo group. In phase I, children received 1 treatment for each eye daily. In phase II, the patients received no treatment. Axial length (AL), SER, intraocular pressure (IOP) and atropine-related side effects were assessed at 6 months' intervals. RESULTS: During phase I, the mean change of SER was -0.46±0.30 D in the atropine group, compared to -1.72±1.12 D in the placebo group (P<0.001). The mean change of AL in the atropine group (0.26±0.30 mm) was significantly shorter than that in the placebo group (0.76±0.62 mm, P=0.002). In addition, in phase II (12mo after the withdrawal of atropine), there was no significant difference in AL change from the atropine group, when compared with that from the placebo group (0.31±0.25 mm vs 0.28±0.26 mm, P>0.05). Furthermore, the change in SER from the atropine group was 0.50±0.41 D, which was significantly lower than 0.72±0.60 D from placebo group, (P<0.05). Finally, there were no statistically significant differences in IOP between the treatment and control groups at any stages (all P>0.05). CONCLUSION: The use of 0.05% atropine for two consecutive years may effectively control elongation of AL and thus progression of myopia, without significant SER progression 1y after atropine withdrawal. Therefore, treatment with 0.05% atropine daily for 2y is effective and safe.http://ies.ijo.cn/en_publish/2023/6/20230617.pdfatropineaxial lengthspherical equivalent refractionchildrenmyopia |
| spellingShingle | Qin Zhu Guang-Yong Tang Zhi-Juan Hua Li-Ping Xue Yuan Zhou Jie-Ying Zhang Ying-Ting Zhu Xiao-Fan Zhang 0.05% atropine on control of myopia progression in Chinese school children: a randomized 3-year clinical trial International Journal of Ophthalmology atropine axial length spherical equivalent refraction children myopia |
| title | 0.05% atropine on control of myopia progression in Chinese school children: a randomized 3-year clinical trial |
| title_full | 0.05% atropine on control of myopia progression in Chinese school children: a randomized 3-year clinical trial |
| title_fullStr | 0.05% atropine on control of myopia progression in Chinese school children: a randomized 3-year clinical trial |
| title_full_unstemmed | 0.05% atropine on control of myopia progression in Chinese school children: a randomized 3-year clinical trial |
| title_short | 0.05% atropine on control of myopia progression in Chinese school children: a randomized 3-year clinical trial |
| title_sort | 0 05 atropine on control of myopia progression in chinese school children a randomized 3 year clinical trial |
| topic | atropine axial length spherical equivalent refraction children myopia |
| url | http://ies.ijo.cn/en_publish/2023/6/20230617.pdf |
| work_keys_str_mv | AT qinzhu 005atropineoncontrolofmyopiaprogressioninchineseschoolchildrenarandomized3yearclinicaltrial AT guangyongtang 005atropineoncontrolofmyopiaprogressioninchineseschoolchildrenarandomized3yearclinicaltrial AT zhijuanhua 005atropineoncontrolofmyopiaprogressioninchineseschoolchildrenarandomized3yearclinicaltrial AT lipingxue 005atropineoncontrolofmyopiaprogressioninchineseschoolchildrenarandomized3yearclinicaltrial AT yuanzhou 005atropineoncontrolofmyopiaprogressioninchineseschoolchildrenarandomized3yearclinicaltrial AT jieyingzhang 005atropineoncontrolofmyopiaprogressioninchineseschoolchildrenarandomized3yearclinicaltrial AT yingtingzhu 005atropineoncontrolofmyopiaprogressioninchineseschoolchildrenarandomized3yearclinicaltrial AT xiaofanzhang 005atropineoncontrolofmyopiaprogressioninchineseschoolchildrenarandomized3yearclinicaltrial |